Clinical Trials Browser

Phase 2 × Multiple Myeloma × Ado-Trastuzumab Emtansine × Clear all

NCT04439110 2025-11-21

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Phase 2 Active not recruiting

38 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms